Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

REHABILITATION & NEUROLOGICAL SERVICES LLC

NPI: 1649690959 · HUNTSVILLE, AL 35805 · Clinical Medical Laboratory · NPI assigned 04/25/2014

$84K
Total Medicaid Paid
1,541
Total Claims
1,123
Beneficiaries
7
Codes Billed
2018-01
First Month
2022-05
Last Month

Provider Details

Authorized OfficialSAVAGE-EDWARDS, BELINDA (OWNER)
Parent OrganizationREHABILITATION & NEUROLOGICAL SERVICES LLC
NPI Enumeration Date04/25/2014

Related Entities

Other providers sharing the same authorized official: SAVAGE-EDWARDS, BELINDA

ProviderCityStateTotal Paid
REHABILITATION & NEUROLOGICAL SERVICES LLC HUNTSVILLE AL $1.25M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,079 $55K
2019 361 $29K
2022 101 $0.00

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 500 273 $35K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 683 508 $23K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 61 58 $13K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 204 196 $9K
87632 40 38 $3K
87581 40 38 $690.90
87486 13 12 $0.00